SI0808312T1 - - Google Patents

Info

Publication number
SI0808312T1
SI0808312T1 SI9630257T SI9630257T SI0808312T1 SI 0808312 T1 SI0808312 T1 SI 0808312T1 SI 9630257 T SI9630257 T SI 9630257T SI 9630257 T SI9630257 T SI 9630257T SI 0808312 T1 SI0808312 T1 SI 0808312T1
Authority
SI
Slovenia
Application number
SI9630257T
Inventor
Laramie M Gaster
Paul A Wyman
Keith R Mulholland
David T Davies
David M Duckworth
Ian T Forbes
Graham E Jones
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9502052.5A external-priority patent/GB9502052D0/en
Priority claimed from GBGB9508327.5A external-priority patent/GB9508327D0/en
Priority claimed from GBGB9508967.8A external-priority patent/GB9508967D0/en
Priority claimed from GBGB9516845.6A external-priority patent/GB9516845D0/en
Priority claimed from GBGB9517542.8A external-priority patent/GB9517542D0/en
Priority claimed from GBGB9518574.0A external-priority patent/GB9518574D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SI0808312T1 publication Critical patent/SI0808312T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
SI9630257T 1995-02-02 1996-01-26 SI0808312T1 (he)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9502052.5A GB9502052D0 (en) 1995-02-02 1995-02-02 Novel compounds
GBGB9508327.5A GB9508327D0 (en) 1995-04-25 1995-04-25 Novel compounds
GBGB9508967.8A GB9508967D0 (en) 1995-05-03 1995-05-03 Novel compounds
GBGB9516845.6A GB9516845D0 (en) 1995-08-17 1995-08-17 Novel compounds
GBGB9517542.8A GB9517542D0 (en) 1995-08-26 1995-08-26 Novel compounds
GBGB9518574.0A GB9518574D0 (en) 1995-09-12 1995-09-12 Novel compounds
EP96902259A EP0808312B1 (en) 1995-02-02 1996-01-26 Indole derivatives as 5-ht receptor antagonist
PCT/EP1996/000368 WO1996023783A1 (en) 1995-02-02 1996-01-26 Indole derivatives as 5-ht receptor antagonist

Publications (1)

Publication Number Publication Date
SI0808312T1 true SI0808312T1 (he) 2001-02-28

Family

ID=27547235

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630257T SI0808312T1 (he) 1995-02-02 1996-01-26

Country Status (34)

Country Link
US (3) US5990133A (he)
EP (1) EP0808312B1 (he)
JP (1) JPH10513442A (he)
KR (1) KR19980701879A (he)
CN (1) CN1151147C (he)
AP (1) AP657A (he)
AR (1) AR002705A1 (he)
AT (1) ATE197300T1 (he)
AU (1) AU699727B2 (he)
BG (1) BG101806A (he)
BR (1) BR9607016A (he)
CA (1) CA2212061A1 (he)
CZ (1) CZ294097B6 (he)
DE (1) DE69610822T2 (he)
DK (1) DK0808312T3 (he)
EA (1) EA000304B1 (he)
ES (1) ES2151652T3 (he)
FI (1) FI973205A (he)
GR (1) GR3035075T3 (he)
HK (1) HK1003883A1 (he)
HU (1) HU223601B1 (he)
IL (1) IL116998A (he)
MA (1) MA23792A1 (he)
MY (1) MY132229A (he)
NO (1) NO313520B1 (he)
NZ (1) NZ301265A (he)
OA (1) OA10502A (he)
PL (1) PL184490B1 (he)
PT (1) PT808312E (he)
RO (1) RO115522B1 (he)
SI (1) SI0808312T1 (he)
SK (1) SK103897A3 (he)
TR (1) TR199700749T1 (he)
WO (1) WO1996023783A1 (he)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ294097B6 (cs) * 1995-02-02 2004-10-13 Smithklineábeechamáplc Indolový derivátŹ způsob jeho přípravy a farmaceutická kompozice s jeho obsahem
GB9517559D0 (en) * 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
GB9612885D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
GB9612883D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6541209B1 (en) 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6420541B1 (en) 1998-04-14 2002-07-16 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9710523D0 (en) * 1997-05-23 1997-07-16 Smithkline Beecham Plc Novel compounds
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
AU3030899A (en) * 1998-02-25 1999-09-15 Smithkline Beecham Plc Process(es) for the preparation of 6-trifluoromethyl-indoline derivatives
CA2325559A1 (en) * 1998-04-14 1999-10-21 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1200086A4 (en) * 1999-08-04 2009-05-27 Icagen Inc THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
AUPQ319899A0 (en) * 1999-10-01 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
EP1264820A4 (en) * 2000-03-14 2004-09-15 Fujisawa Pharmaceutical Co amide compounds
US6448293B1 (en) 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
FR2807754A1 (fr) * 2000-04-13 2001-10-19 Adir Nouveaux derives de cyclobuta-indole carboxamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
GB0019950D0 (en) * 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US6610747B2 (en) 2000-08-31 2003-08-26 Pfizer Inc. Phenoxybenzylamine derivatives as SSRIs
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
GB2380190A (en) * 2001-08-28 2003-04-02 Bayer Ag Antiinflammatory heterocyclic sulphones
CA2462135C (en) 2001-09-29 2014-12-30 Lg Electronics Inc. Method for transferring and /or receiving data in communication system and apparatus thereof
MXPA04004674A (es) 2001-11-14 2004-08-12 Schering Corp Ligados de los receptors de los canabinodies.
GB0200283D0 (en) * 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
CA2480880C (en) 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibitors of akt activity
AU2003243637A1 (en) 2002-06-19 2004-01-06 Schering Corporation Cannabinoid receptor agonists
US20060063782A1 (en) * 2002-07-03 2006-03-23 Murray Christopher W 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
US7091216B2 (en) 2002-08-02 2006-08-15 Merck & Co., Inc. Substituted furo[2,3-b]pyridine derivatives
CA2494164A1 (en) * 2002-08-23 2004-03-04 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
AU2003284981B2 (en) 2002-10-30 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
JP2006511587A (ja) * 2002-12-20 2006-04-06 ミジェニックス コーポレイション アデニンヌクレオチドトランスロカーゼ（ａｎｔ）リガンドならびにそれに関連する組成物および方法
AU2003300360A1 (en) * 2002-12-20 2004-07-22 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
WO2004058722A1 (en) * 2002-12-24 2004-07-15 Arena Pharmaceuticals, Inc. Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004096130A2 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
JP2006524641A (ja) * 2003-04-25 2006-11-02 ハー・ルンドベック・アクチエゼルスカベット 置換されたインドリンおよびインドール誘導体
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2005002673A1 (en) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
CN1826322B (zh) * 2003-07-22 2012-04-18 艾尼纳制药公司 用于预防和治疗相关病症而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
US7517900B2 (en) 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
CA2559038C (en) 2004-03-23 2013-09-10 Arena Pharmaceuticals, Inc. Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
KR101366414B1 (ko) * 2004-09-02 2014-03-18 쿠리스 인코퍼레이션 헤지호그 신호전달에 대한 피리딜 억제제
SA05260357B1 (ar) * 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
US20080015223A1 (en) * 2004-12-03 2008-01-17 Arena Pharmaceuticals, Inc. Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
US20080200530A1 (en) * 2005-01-19 2008-08-21 Unett David J Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy
JP5212101B2 (ja) * 2005-09-02 2013-06-19 アステラス製薬株式会社 新規化合物
EP2202222A3 (en) 2005-11-08 2010-09-15 Laboratorios Del Dr. Esteve, S.A. Indene derivatives, their preparation and use as medicaments
WO2007136703A1 (en) 2006-05-18 2007-11-29 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
AU2007254244C1 (en) 2006-05-18 2014-07-31 Arena Pharmaceuticals, Inc. 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
CN102827081A (zh) 2006-05-18 2012-12-19 艾尼纳制药公司 用作5-ht2a 血清素受体调节剂的苯基-吡唑的晶型和其制备方法
UA95298C2 (ru) * 2006-07-07 2011-07-25 Бьёрингер Ингельхайм Интернациональ Гмбх Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
EP1884515A1 (en) 2006-07-31 2008-02-06 Laboratorios del Dr. Esteve S.A. Substituted indanyl sulfonamide compounds, their preparation and use as medicaments
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
LT2848610T (lt) 2006-11-15 2017-11-10 Ym Biosciences Australia Pty Ltd Kinazės aktyvumo inhibitoriai
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
CA2692379A1 (en) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
CL2008001943A1 (es) * 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
DE602007012683D1 (de) 2007-07-19 2011-04-07 Esteve Labor Dr Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US20110021538A1 (en) * 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
CA2738448A1 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh New chemical compounds
EP2364142B1 (en) * 2008-10-28 2018-01-17 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CN102348798A (zh) 2009-01-16 2012-02-08 麻省理工学院 孤独症谱系障碍的诊断和治疗
EP2477630A4 (en) * 2009-09-17 2013-05-01 Univ Vanderbilt SUBSTITUTED BENZAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS, AND METHODS OF PREPARING AND USING SAME
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2012051502A1 (en) * 2010-10-14 2012-04-19 University Of Utah Research Foundation Methods and compositions related to neuroactive thiazoline compounds
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
PL2762466T3 (pl) * 2011-09-29 2017-09-29 Ono Pharmaceutical Co., Ltd. Pochodna fenylu
EP2763532B1 (en) 2011-10-05 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Pi-kinase inhibitors with broad spectrum anti-infective activity
US9926309B2 (en) 2011-10-05 2018-03-27 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2014114928A1 (en) 2013-01-23 2014-07-31 Astrazeneca Ab Chemical compounds
WO2015077246A1 (en) 2013-11-19 2015-05-28 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
EP3419980A4 (en) 2016-02-26 2019-07-03 The Board of Trustees of the Leland Stanford Junior University INHIBITORS OF PI-KINASE WITH ANTI-INFECTIOUS ACTIVITY
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
MD3664802T2 (ro) 2017-08-07 2022-07-31 Alkermes Inc Inhibitori biciclici ai deacetilazei histonei
CA3089630A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
EP4013412A1 (en) 2019-08-12 2022-06-22 Deciphera Pharmaceuticals, LLC Ripretinib for treating gastrointestinal stromal tumors
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4084779B1 (en) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
EP4084778B1 (en) 2019-12-30 2023-11-01 Deciphera Pharmaceuticals, LLC Amorphous kinase inhibitor formulations and methods of use thereof
AU2022415426A1 (en) * 2021-12-15 2024-07-25 Delix Therapeutics, Inc. Fused pyrrolidine psychoplastogens and uses thereof
TW202333668A (zh) * 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
WO2023114325A1 (en) * 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Constrained amine psychoplastogens and uses thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL242547A (he) * 1958-08-22
SE370866B (he) * 1968-03-21 1974-11-04 Ciba Geigy Ag
KR930702334A (ko) * 1990-09-13 1993-09-08 데이비드 로버트 5 하이드록시트립타민 수용체 길항제로서의 인돌우레아
AU4704693A (en) * 1992-08-20 1994-03-15 Smithkline Beecham Plc Condensed indole derivatives as 5HT-2C and 5HT-2B antagonists
GB9306460D0 (en) * 1993-03-29 1993-05-19 Smithkline Beecham Plc Novel compounds
GB9313913D0 (en) * 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds
CZ294097B6 (cs) * 1995-02-02 2004-10-13 Smithklineábeechamáplc Indolový derivátŹ způsob jeho přípravy a farmaceutická kompozice s jeho obsahem

Also Published As

Publication number Publication date
NZ301265A (en) 1998-12-23
OA10502A (en) 2002-04-12
NO313520B1 (no) 2002-10-14
CN1151147C (zh) 2004-05-26
HK1003883A1 (en) 1998-11-13
BR9607016A (pt) 1997-10-28
DE69610822D1 (de) 2000-12-07
DK0808312T3 (da) 2001-02-12
SK103897A3 (en) 1998-02-04
BG101806A (en) 1998-04-30
JPH10513442A (ja) 1998-12-22
IL116998A0 (en) 1996-09-12
TR199700749T1 (xx) 1998-02-21
CA2212061A1 (en) 1996-08-08
PL321706A1 (en) 1997-12-22
DE69610822T2 (de) 2001-06-07
US20030105139A1 (en) 2003-06-05
AP9701036A0 (en) 1997-07-31
HU223601B1 (hu) 2004-10-28
EA000304B1 (ru) 1999-04-29
CZ294097B6 (cs) 2004-10-13
US6235758B1 (en) 2001-05-22
WO1996023783A1 (en) 1996-08-08
PT808312E (pt) 2001-03-30
ES2151652T3 (es) 2001-01-01
NO973543D0 (no) 1997-08-01
CN1179156A (zh) 1998-04-15
AP657A (en) 1998-08-06
AR002705A1 (es) 1998-04-29
CZ244597A3 (cs) 1998-09-16
AU4664696A (en) 1996-08-21
US6638953B2 (en) 2003-10-28
PL184490B1 (pl) 2002-11-29
NO973543L (no) 1997-10-01
EA199700156A1 (ru) 1997-12-30
EP0808312B1 (en) 2000-11-02
HUP9901115A2 (hu) 1999-07-28
HUP9901115A3 (en) 2000-02-28
IL116998A (he) 2001-08-08
EP0808312A1 (en) 1997-11-26
ATE197300T1 (de) 2000-11-15
FI973205A (fi) 1997-10-01
US5990133A (en) 1999-11-23
MY132229A (en) 2007-09-28
AU699727B2 (en) 1998-12-10
RO115522B1 (ro) 2000-03-30
KR19980701879A (ko) 1998-06-25
FI973205A0 (fi) 1997-08-01
GR3035075T3 (en) 2001-03-30
MA23792A1 (fr) 1996-10-01

Similar Documents

Publication Publication Date Title
DE69638352D1 (he)
DE69637714D1 (he)
BR122012014331A2 (he)
BRPI9612258B1 (he)
BRPI9612138B1 (he)
DK143195A (he)
CH0741373H1 (he)
DK0727898T3 (he)
BR7501503U (he)
BR7502120U (he)
DK126096A (he)
CN3032568S (he)
CN3034473S (he)
CN3030489S (he)
CN3030542S (he)
CN3030543S (he)
CN3031001S (he)
CN3031350S (he)
CN3031655S (he)
CN3031742S (he)
CN3031926S (he)
CN3032332S (he)
CN3032390S (he)
CN3032522S (he)
CN3030296S (he)